Jefferies 2015 Healthcare Conference
|
|
- Georgia Ford
- 5 years ago
- Views:
Transcription
1 Jefferies 2015 Healthcare Conference Paul J. Hastings Chairman and Chief Executive Officer June 2, 2015
2 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included in these slides and accompanying oral presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, could, will, would, should, expect, plan, anticipate, believe, estimate, intend, predict, seek, contemplate, potential or continue or the negative of these terms or other comparable terminology. Forward-looking statements in these slides and accompanying oral presentation include, but are not limited to, statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance product candidates into, and successfully complete, clinical trials; the tolerability of our product candidates at efficacious doses; our collaborators exercise of their license options; the commercialization of our product candidates; the implementation of our business model, strategic plans for our business, product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the timing or likelihood of regulatory filings and approvals; our ability to maintain and establish collaborations or obtain additional government grant funding; our financial performance; and developments relating to our competitors and our industry. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; our dependence on our collaboration partners, including Celgene, GlaxoSmithKline and Bayer, for the funding of our partnered programs; our ability to raise additional capital to support the development of our unpartnered programs; our dependence on the development and marketing efforts of our partners for the commercial success of our partnered product candidates; our reliance on third parties to conduct certain preclinical studies and all of our clinical trials; our reliance on single source third-party contract manufacturing organizations to manufacture and supply our product candidates; our ability to validate, develop and obtain regulatory approval for companion diagnostics; our ability to achieve market acceptance and commercial success of our product candidates once regulatory approval is achieved; our ability to discover, develop and commercialize additional product candidates; the ability of competitors to discover, develop or commercialize competing products more quickly or more successfully; our dependence on our Chairman and Chief Executive Officer, our Chief Scientific Officer, our Chief Medical Officer and other key executives; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate our patents or proprietary rights; and the ability of our proprietary rights to protect our technologies and product candidates. Other factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Risk Factors or otherwise described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the Securities and Exchange Commission (SEC) on March 12, 2015 and our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2015, filed with the SEC on May 7, Any forward-looking statement you see or hear during this presentation reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forwardlooking statements for any reason, even if new information becomes available in the future. 2
3 OncoMed Pharmaceuticals, Inc. Proprietary Discovery Capabilities Targeting critical cancer stem cell and immuno-oncology pathways Pipeline of first-in-class anti-cancer stem cell therapeutics All discovered at OncoMed Deep Clinical Pipeline 6 clinical programs in or advancing to Phase 2 7 th program IND filed 16 active clinical trials: evidence of activity Data from multiple randomized Phase 2 trials by Strong Long-Term Outlook Partnerships with Celgene, Bayer and GSK Ongoing discovery research fueling pipeline Substantial future milestones and cash 3
4 CD44 Tumor Volume (mm3) CD44 Cancer Stem Cells Drive Tumor Growth, Recurrence and Metastasis CSCs Drive Tumor Growth Human colon tumor CSCs Anti-CSC Therapy Blocks Renewal; Forces Differentiation CD166 Self-renewal CSC (7/8) Human colon tumor growth in mouse xenograft Other (0/10) Day post-injection Differentiation FACS analysis of human tumor in mouse CSCs CD166 4
5 Targeting Critical Stem Cell Pathways Notch Pathway Wnt Pathway RSPO/LGR Pathway New Pathways Demcizumab Vantictumab Anti-RSPO3 Immunotherapy Tarextumab Ipafricept Other RSPOs Hippo Brontictuzumab Anti-DLL4/VEGF bispecific Small Molecules Other LGRs Undisclosed 5
6 PRECLINICAL CLINICAL Anti-Cancer Stem Cell Pipeline 6 Clinical Programs, 5+ Research Programs Therapeutic Preclinical IND Phase 1a Phase 1b Phase 2 Demcizumab Anti-DLL4; OMP-21M18 Tarextumab Anti-Notch2/3; OMP-59R5 Vantictumab anti-fzd7, OMP-18R5 Ipafricept Fzd8-Fc; OMP-54F28 Brontictuzumab Anti-Notch1; OMP-52M51 Anti-DLL4/VEGF OMP-305B83 Anti-RSPO3 OMP-131R10 Filed Small Molecules WNT inhibitors Immunotherapy Hippo Pathway Small Molecules (Undisclosed) 6
7 Demcizumab (anti-dll4) Inhibits Tumor Growth by Three Distinct Mechanisms Blocking DLL4 function reduces CSC, inhibits tumor angiogenesis and relieves immune suppression Cancer Stem Cells Angiogenesis Immune Response Promotes differentiation and chemo sensitization Blocks critical DLL4 role in angiogenesis Reduced IL-17 production Reduced monocytic myeloid-derived suppressor cells (MDSCs) 7
8 Demcizumab Clinical Program Single agent Combo with chemo Randomized Phase 1b Pancreatic Cancer Phase 2 YOSEMITE Pancreatic Cancer Enrolling Phase 1a Advanced solid tumors Phase 1b Non-Small Cell Lung Phase 2 DENALI NSCLC Enrolling Phase 1b/2 Ovarian Currently In Ph1b Multi-pronged MOA Single agent activity observed partial and minor responses Generally well tolerated Truncated dosing mitigates cardiopulmonary toxicity 8
9 % Change in Tumor Size Demcizumab Phase 1b Pancreatic Cancer Response Rates First-line Pancreatic Cancer (N=29) Demcizumab + Gemcitabine + Abraxane 89% Overall Clinical Benefit Rate Demcizumab + Abraxane + Gemcitabine* (N=29) Abraxane + Gemcitabine** Partial Response 14 (50%) 23% Stable Disease 11 (39%) 27% Hidalgo, et al ASCO 2015 * Single arm study, unconfirmed responses **MPACT Phase 3 study; Von Hoff, et al, NEJM
10 Probability Probability Demcizumab Phase 1b Pancreatic Cancer Duration of Responses Progression-free Survival Demcizumab + Abraxane + Gemcitabine mpfs (95% CI) = 9.0 months (3.7 NR) Overall Survival Demcizumab + Abraxane + Gemcitabine mos (95% CI) = 10.1 months ( ) Months Months Survival Rates Demcizumab + Abraxane + Gemcitabine* Abraxane + Gemcitabine** Progression-free Survival 9.0 months 5.5 months Overall Survival 10.1 months 8.5 months Hidalgo, et al ASCO 2015 *Single arm study, unconfirmed responses **MPACT Phase 3 study; Von Hoff, et al, NEJM
11 % Change in Tumor Size Demcizumab Phase 1b NSCLC Response Rates First-Line Advanced NSCLC (N=40) Demcizumab + Pemetrexed + Carboplatin Kotasek, et al ASCO % Overall Clinical Benefit Rate Demcizumab + Pemetrexed + Carboplatin (N=40)* Complete Response 1 (3%) Pemetrexed + Carboplatin** Partial Response 19 (48%) 27% Stable Disease 15 (38%) * Single arm study, unconfirmed responses ** Alimta (pemetrexed) Package insert 11
12 Overall Survival % Alive % Alive NSCLC Overall Survival by Kaplan Meier Phase 1b Exploratory Analysis Continuous Demcizumab Dosing Worst Case Survival Analysis Truncated Demcizumab Dosing mos (95% CI) = 8.1 (5.8-NR) mos mos (95% CI) = 6.3 months (3.2-NR) Months Tumor Biomarker Analysis (%Tils) % %TILs >50% Months Ten of 23 patients (~40%) alive >2 years %TILs 50% %TILs 50% Kotasek, ASCO 2015 Survival days 12
13 Tarextumab: Anti-Notch2/3 Antibody Single agent Combo with chemo Randomized Phase 1a Advanced solid tumors Phase 1b/2 ALPINE Phase Study 1b/2 Pancreatic ALPINE Cancer Pancreatic Phase 1b/2 PINNACLE Study Phase 1b/2 Small Cell PINNACLE Lung Cancer Small Cell Lung Cancer Enrolling Enrolling Reduces CSCs; promotes differentiation Single agent activity On-target, manageable GI toxicities Predictive biomarker program Notch3+ tumor status 13
14 % Change in Tumor Size Tarextumab Phase 1b ALPINE Response Rates First-line Pancreatic Cancer (N=37) Tarextumab + Abraxane + Gemcitabine = Tarextumab + Gemcitabine = Tarextumab + Gemcitabine + Abraxane 30% target tumor reduction 73% Overall Clinical Benefit Rate Tarextumab + Abraxan+ Gemcitabinee* (N=24) Abraxane + Gemcitabine** Partial Response 11 (38%) 23% Stable Disease 10 (35%) 27% PR + SD 21 (73%) 50% O Reilly, et al ASCO GI 2015 *Single arm study, unconfirmed responses **MPACT Phase 3 study; Von Hoff, et al, NEJM
15 Tarextumab Phase 1b ALPINE Duration and Biomarker Data Tumor Notch3 Level and Timed Endpoints 14.6months O Reilly, et al ASCO GI 2015 Progression-free Survival and Overall Survival Tarextumab + Gemcitabine + Abraxane* mpfs (months) mos (months) All patients (N=24) Notch3 high (50%) (N=12) Gemcitabine + Abraxane** *Single arm study, unconfirmed responses **MPACT Phase 3 study; Von Hoff, et al, NEJM
16 % Change in Tumor Size Tarextumab Phase 1b PINNACLE Response Rates Extensive-stage SCLC (N=26) Tarextumab + Etoposide + Cisplatin/Carboplatin 100% Overall Clinical Benefit Rate (N=26) Tarextumab + Etoposide + Carboplatin/Cisplatin Cisplatin + Etoposide** Partial Response 20 (77%) 44%-67% Stable Disease 6 (23%) Pietanza, et al ASCO 2015 * Single arm study, unconfirmed responses **SCLC Meta-Analysis; Rossi, et al, JCO
17 Tarextumab Phase 1b PINNACLE Biomarker and Survival Analysis Progression-Free Survival Low Notch3 vs. High Notch3 Overall Survival Low Notch3 vs. High Notch3 Low Notch 3 N=12 High Notch 3 N=13 Low Notch 3 N=12 High Notch 3 N=13 N=13 Months Months Months Months Potentially longer survival noted in Notch3 high patients receiving higher doses of tarextumab ( 12.5mg/kg) + platinum therapy Pietanza, et al ASCO
18 Brontictuzumab: Anti-Notch1 Antibody Dose Escalation Expansion Cohort Phase 1a Advanced solid tumors Phase 1a Biomarker selected Ongoing expansion Phase 1a Hematologic malignancies Phase 1a Biomarker selected Ongoing dose escalation Anti-CSC, anti-angiogenic Single agent activity On-target, manageable GI toxicities Predictive biomarker program IHC assay identifying solid tumors with Notch1 activation 18
19 Brontictuzumab Phase 1a Solid Tumor Trial with Biomarker Assay Partial Response Stable Disease Progressive Disease Total Responses among Evaluable Subjects (N=17) Notch1 High Notch1 Low Notch1? Predictive Biomarker (Notch1) 3 of 4 patients with Notch1 ICD high tumors with clinical benefit 1 of 9 patients with Notch1 ICD low tumors with clinical benefit Phase 1a Expansion Now Enrolling Solid Tumor Types with Notch1 ICD High Prevalence (12%-53%) Colorectal Gastric Esophageal Pancreatic Small cell lung HER2- breast Cholangiocarcinoma Adenoid cystic carcinoma Patnaik, et al EORTC-NCI-AACR
20 Vantictumab (anti-fzd7) WNT Pathway Single agent Phase 1a Advanced solid tumors Combo with chemo Phase 1b Her2- Breast Cancer paclitaxel Phase 1b NSCLC docetaxel Phase 1b Pancreatic Cancer gemcitabine + Abraxane Inhibits Wnt signaling Blocks Frizzled 1, 2, 5, 7, 8 On-target, mild-to-moderate bone-related AEs observed Bone protection strategy Single agent activity 3/3 neuroendocrine tumors 20
21 Ipafricept (Fzd8-FC) WNT Pathway Single agent Combo with chemo Phase 1b Ovarian carboplatin + paclitaxel Phase 1a Advanced solid tumors Phase 1b Hepatocellular sorafenib Phase 1b Pancreatic gemcitabine + Abraxane Inhibits signaling: binds Wnt ligands Distinct from vantictumab On-target, mild-to-moderate bone-related AEs observed Bone protection strategy Single agent activity in diverse tumor types; SD > 112 days in 9 patients 21
22 Anti-DLL4/VEGF Bispecific (OMP-305B83) Single agent Anti- VEGF Heavy chain Anti-DLL4 Heavy chain Phase 1a Advanced solid tumors Dual inhibitor DLL4 & VEGF Multi-pronged MOA Preclinical data: improved efficacy and safety Phase 1a initiated December 2014 Dose escalation, expansion Advanced, refractory solid tumors Yen AACR
23 New R&D Candidates Anti-RSPO3 (OMP-131R10) IND filed April 2015 Multiple therapeutic opportunities Strong predictive biomarker strategy Broad, issued claims cover therapeutic antibodies that disrupt RSPO-LGR signaling RSPO LGR Immuno-oncology Two novel immuno-oncology programs Hippo pathway (Celgene) GITR Ligand-Fc (OMED wholly owned) Discovery of missing checkpoint receptor to PD-L2 OMED wholly owned GITRL-Fc Other Anti-RSPO candidates RSPO 1, 2, 4; LGR 4, 5, 6 Gurney AACR
24 3 Significant Partnerships Provide Funding and Value Partner Year Upfront Comments 2013 $177M* 2010 $40M 2007, 2011 $35M* Up to 6 biologics + small molecules Co-development/commercialization on 5 of 6 biologics Demcizumab end of Phase 2 opt-in Anti-DLL4/VEGF, RSPO3, others Phase 1 opt-in 1/3 OMED 2/3 CELG development cost share US profit share Ex-US royalties Celgene equity stake ~5% Up to 3 biologic & 2 small molecule programs Opt-in through end of Phase 1b for vantictumab, ipafricept Mid-single digit to high teens royalties on biologics 2 biologics programs Opt-in at end of Phase 2 for tarextumab Opt-in at end of Phase 1 or Phase 2 for brontictuzumab Low double-digit to high teens royalties GSK equity stake ~8.8% *Celgene: $155M cash, $22.25 equity; GSK: $17.5M cash, $17.5M equity Note: equity % stake per most recent SEC filing 24
25 Program Financial Milestone Snapshot Program Potential Future Milestones/Payments Demcizumab ~$790M Tarextumab $319.5M Vantictumab $357.5M Ipafricept $347.5M Brontictuzumab $330.5M Anti-DLL4/VEGF bispecific ~$505M Anti-RSPO3 ~$440M RSPO/undisclosed pathway ~$440M each, up to 3 Bayer small molecules $110M Celgene small molecules >$100M Total Potential Milestones >$4 Billion Over $378M* received to date from Celgene, Bayer, GSK *Includes $5M receivable 25
26 Potential Collaborative Revenue Milestone/Payments Partner Amount Timing Brontictuzumab Phase 1 expansion Demcizumab Phase 2 safety analysis $5M 1H 2015 $70M Q4 2015/2016 Vantictumab opt-in $25M 2H 2015/2016 Ipafricept opt-in $15M 2H 2015/2016 Brontictuzumab opt-in $18.75M 2H 2015/2016 Payment increases to $25M if GSK chooses to wait to opt in at Phase 2 Tarextumab opt-in $25M 2016 Total Potential Milestones >$150M Through 1H 2016* * Additional milestones could be achieved in 2015/2016 related to preclinical and small molecule programs 26
27 OMED Financial Guidance Cash*: $213M as of March 31, Financial Guidance: $100 - $110M cash operating expenses, excluding non-cash expenses YE cash of over $120M before potential milestone payments $150M+ in potential 2015/16 payments from existing partnerships Existing cash plus future milestones may fund operations through commercialization without need for future financing * Cash, equivalents, and short-term investments; unaudited 27
28 2015 Pipeline Progress 1H 2015 Anti-DLL4/VEGF Phase 1a FPI ASCO GI - Tarextumab Final Phase 1b pancreatic; biomarker Phase1a Brontictuzumab expansion Demcizumab NSCLC Phase 2 FPI Demcizumab Pancreatic Phase 2 FPI ELCC - Demcizumab Updated Phase 1b NSCLC data AACR 7 abstracts accepted for presentation R&D Investor Day April 29 in NYC File anti-rspo3 IND ASCO - Tarextumab Phase 1b SCLC ASCO - Demcizumab Phase 1b Pancreatic & NSCLC Financial/Corporate* 2H 2015 Complete Demcizumab Phase 1b Ovarian Anti-RSPO3 Phase 1a FPI Complete Tarextumab Phase 2 enrollment in pancreatic cancer Present Phase 1a Brontictuzumab data Biomarker-selected expansion cohort Present Ipafricept data Present Vantictumab data Present opt-in package to Bayer Vantictumab & ipafricept Demcizumab Phase 2 safety analysis * Select financial milestones Data 2015 / 2016 Clinical 28
29 OncoMed Pharmaceuticals, Inc. Proprietary Discovery Capabilities Targeting critical cancer stem cell and immuno-oncology pathways Pipeline of first-in-class anti-cancer stem cell therapeutics All discovered at OncoMed Deep Clinical Pipeline 6 clinical programs in or advancing to Phase 2 7 th program IND filed 16 active clinical trials: evidence of activity Data from multiple randomized Phase 2 trials by Strong Long-Term Outlook Partnerships with Celgene, Bayer and GSK Ongoing discovery research fueling pipeline Substantial future milestones and cash 29
30 Thank you
OncoMed Pharmaceuticals Jefferies Healthcare Conference. Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016
OncoMed Pharmaceuticals Jefferies Healthcare Conference Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016 Safe Harbor Statement These slides and accompanying oral presentation
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationPaul J. Hastings Chairman and CEO. October 2013
Targeting Cancer Stem Cells Paul J. Hastings Chairman and CEO October 2013 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationMerus. Corporate Presentation. November 15, 2018
Merus Corporate Presentation November 15, 2018 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationSafe Harbor Statement
September 2007 Safe Harbor Statement During the course of this presentation we will make forward-looking statements that involve risks and uncertainties associated with a developing pharmaceutical company.
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCreating and developing innovative therapies. Deborah Rathjen CEO & Managing Director
Creating and developing innovative therapies Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationCelldex Provides Corporate Update and Reports First Quarter 2018 Results
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationClinical Development for Patients with Cancer
OMP 59R5: a Novel Therapeutic Antibody in Clinical Development for Patients with Cancer Jakob Dupont, MD, MA Chief Medical Officer and Senior Vice President OncoMed Pharmaceuticals Inc. Adjunct Clinical
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationJefferies 2015 Global Healthcare Conference June 1, 2015
Jefferies 2015 Global Healthcare Conference June 1, 2015 Page 0 Acceleron Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements are neither historical
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More information